Monday, December 23, 2024
spot_img
HomeGeneticsGenetic ResearchMetabolomics and the Microbiome of Breasts

Metabolomics and the Microbiome of Breasts

The prevalence of breast cancer leads to keen interest in identifying exactly what happens in healthy and diseased cells.  Breast tissue has traditionally been considered sterile.  With the aid of metabolomics, we know that the breast has its own microbiome. And the health of the breast microbiome depends on the health of the gut microbiome.  The metabolites of various organisms can now be identified and quantitated leading to identification of the bacterial inhabitants of the breast microbiome both in health and in disease.

The metabolites of various bacteria are modulators of our body’s functioning including inflammation proliferation and cell death.  These metabolites can serve as biomarkers for healthy or diseased tissues

Its’s been suggested that one should be limiting supplementing the hormone progesterone or even that endogenous progesterone is a danger. Progesterone may be metabolized to pregnanes and pregnenes which in turn cause cell proliferation and tumor growth.  However, this conversion requires the action of an enzyme, 5 alpha reductase and the presence of bacillus cereus to metabolize progesterone in this pathway.  The bacteria may be the source of aberrant metabolism of progesterone. Rather than limiting an essential hormone, the key may be restoring a healthy gut and breast microbiome.

There are other examples of activity of bacterial metabolites Lithocholic acid, short-chain fatty acids, indole-propionic acid or cadaverine can limit the proliferation of breast cancer cells and now can be identified.   An association of low Faecalibacterium in the gut was linked to the upregulation of phosphocholine in breast cancer patients. Bacterial production of glucuronidase reactivates already conjugated estrogens and may increase estrogen stimulation.

This possibility of identifying the breast microbiome inhabitants in both healthy and diseased tissue may lead to new and better diagnosis and treatments.

Re: Mysoon, M Et all “Metabolomics-Microbiome Crosstalk in the Breast Cancer Microenvironment”  Metabolites  4 November 2021

This article was written by Carol Petersen RPh, CNP an accomplished compounding pharmacist with decades of experience helping patients improve their quality of life through bio-identical hormone replacement therapy. She graduated from the University of Wisconsin School of Pharmacy and is a Certified Nutritional Practitioner. Her passion to optimize health and commitment to compounding is evident in her involvement with organizations including the International College of Integrated Medicine and the American College of Apothecaries, the American Pharmacists Association, and the Alliance for Pharmacy Compounding. She was also the founder and first chair for the Compounding Special Interest Group with the American Pharmacists Association. She serves as chair for the Integrated Medicine Consortium. She co-hosts a radio program “Take Charge of Your Health” in the greater New York area. She is on the Medical Advisory Board for the Centre for Menstrual Cycle and Ovulation Research (CeMCOR.ca). To contact Carol click here

As with anything you read on the internet, this article should not be construed as medical advice; please talk to your doctor or primary care provider before changing your wellness routine.

Content may be edited for style and length.

Materials provided by:

www.thewellnessbydesignproject.com

https://pubmed.ncbi.nlm.nih.gov/34822416/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8619468/

https://www.mdpi.com/2218-1989/11/11/758

RELATED ARTICLES

Most Popular